Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells

• Main Authors: Wei Zhang (Author), Ying-Fang Fan (Author), Chao-Yun Cai (Author), Jing-Quan Wang (Author), Qiu-Xu Teng (Author), Zi-Ning Lei (Author), Leli Zeng (Author), Pranav Gupta (Author), Zhe-Sheng Chen (Author)
• Format: Book
• Published: Frontiers Media S.A., 2018-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The main characteristic of tumor cell resistance is multidrug resistance (MDR). MDR is the principle cause of the decline in clinical efficacy of chemotherapeutic drugs. There are several mechanisms that could cause MDR. Among these, one of the most important mechanisms underlying MDR is the overexp...